TBI Action Alliance is committed to advancing Traumatic Brain Injury (TBI) research and awareness through the TBI Precision Research Roadmap. Here's a glimpse into our 7 lines of effort: 1. Injury burden: Identifying the disease burden across all populations and injury severities. 2. Disease models: Developing translational disease models based on trauma pathogenesis. 3. Precision diagnosis: Validating diagnostic biomarkers for TBI. 4. Targeted therapeutics: Fast-tracking first-generation TBI therapeutics. 5. Clinical practice implementation: Accelerating adoption of best practices and precision therapeutic approaches. 6. Translational infrastructure: Addressing infrastructure and technology gaps. 7. Awareness and advocacy: Placing TBI at the forefront of U.S. public policy and reducing stigma. These efforts are made possible through the power of collaboration. Together, we're identifying research gaps and ensuring a coordinated effort to make a meaningful impact in the lives of those affected by traumatic brain injuries. Interested in joining TBI Action Alliance? Contact us today: bit.ly/3PHHDjh #TBIPrecisionResearch #BrainHealth #TBIActionAlliance #TBIAction
TBI Action Alliance的动态
最相关的动态
-
??CAR-T therapies offer new options for the treatment of neuroimmunological diseases CAR-T cell therapies, known for treating B cell-related cancers, are now being explored for autoimmune diseases. CAR-T cells can penetrate the central nervous system and deplete B cells that cause inflammation, offering targeted and durable responses for neurological autoimmune disorders. Review from Otto-von-Guericke University Magdeburg and FAU Erlangen-Nürnberg in Germany highlights the potential of CAR-T for the treatment of conditions like multiple sclerosis and myasthenia gravis, especially for people unresponsive to conventional treatments. Advancing these therapies through research and clinical trials has the potential to transform treatment landscapes. But to make this a reality, we also need to ensure these therapies are not only approvable but accessible and affordable too. This begins with prioritizing automated manufacturing solutions that can deliver both on biology needs and scale. Read the full review in The Lancet: https://lnkd.in/eMCmix3d #ManufacturingBrighterFutures #PatientAccess #AccelerateProductDevelopment #ScaleYourImpact
-
-
Don't miss our next webinar! Clario's experts will explore the critical aspects of conducting clinical trials in Alzheimer’s disease (AD). Topics will focus on: - The role of imaging biomarkers in characterizing patient eligibility, ensuring safety and evaluating therapeutic efficacy - Challenges associated with collecting endpoints for clinical outcome assessments in a changing patient population - Leveraging gait and balance measures for detection and diagnosis of cognitive impairment and dementia and their significance in early intervention -The complexities of running trials in populations at high risk for cardiovascular (CV) disease, emphasizing the importance of baseline testing regardless of the drug being investigated Register now to gain invaluable insights into Alzheimer's disease research: https://lnkd.in/e9FZwuGs #AlzheimersResearch #EndpointDataCollection #Webinar
-
Alzheimer's researchers, mark the diary for June 13th Webinar covering Imaging endpoints/eligibility; eCOA assessments; Wearables for gait/movement; CV risk management: agenda and registration below ?? #alzheimers #clinicaltrials #neuroscience #dementia #biomarkers
Don't miss our next webinar! Clario's experts will explore the critical aspects of conducting clinical trials in Alzheimer’s disease (AD). Topics will focus on: - The role of imaging biomarkers in characterizing patient eligibility, ensuring safety and evaluating therapeutic efficacy - Challenges associated with collecting endpoints for clinical outcome assessments in a changing patient population - Leveraging gait and balance measures for detection and diagnosis of cognitive impairment and dementia and their significance in early intervention -The complexities of running trials in populations at high risk for cardiovascular (CV) disease, emphasizing the importance of baseline testing regardless of the drug being investigated Register now to gain invaluable insights into Alzheimer's disease research: https://lnkd.in/e9FZwuGs #AlzheimersResearch #EndpointDataCollection #Webinar
Advancing Alzheimer’s Clinical Trial Endpoints: Imaging Biomarkers, COA Challenges, Movement Measures, and CV Risk | Clario
https://clario.com
-
Our on-demand webinar features Dr. Matthew C. Havrda discussing neuroinflammation in Parkinson's disease is now available to stream. Learn how advanced assays are transforming research & clinical trials. #Neuroinflammation #Parkinsons
Driving Scientific Breakthroughs with Advanced Assay Development
go.quanterix.com
-
MSc, PhD, Senior FAS at Quanterix accelerating the early diagnosis of neurodegenerative diseases: Alzheimer, Multiple Sclerosis, through ultrasensitive biomarker detection in liquid biopsies
Our on-demand webinar features Dr. Matthew C. Havrda discussing neuroinflammation in Parkinson's disease is now available to stream. Learn how advanced assays are transforming research & clinical trials. #Neuroinflammation #Parkinsons
Driving Scientific Breakthroughs with Advanced Assay Development
go.quanterix.com
-
Today, PHM has released “The Importance of Clinical Trials in Cancer Care” whitepaper for benefit leaders. This report highlights the critical role of clinical trials in advancing cancer treatment, improving patient outcomes, and lowering costs for employers. Clinical trials are crucial for testing the safety and efficacy of new medical treatments and interventions. However, access to these trials has often been hindered by the clinical and scientific complexity of identifying and prioritizing appropriate trials. PHM is proud of its ability to bridge the gap between groundbreaking medical research and the patients who may benefit from it. Learn how integrating clinical trials into health plans can benefit both patients and employers: https://lnkd.in/gvgUavYm Read the press release: https://lnkd.in/gaSvV2_N Our thanks to PHM’s team of researchers and clinicians for their contribution to this whitepaper - Eva J. Gordon, PhD, Natalya Gertsik, PhD, Tommy Axford, Lee D. Gibbs, Ph.D., Ross Keller, PhD, Erika Sharpe, Amber McDonald, Julie Nowicki, and Zach Doran #clinicalresearch #clinicaltrials #cancercare #employerbenefits #employerhealthplans
The Importance of Clinical Trials in Cancer Care | PHM
solutions.privatehealth.com
-
I improve access to the latest molecular diagnostic tests and cutting edge treatments for cancer parients.
Check out our new whitepaper "The Importance of Clinical Trials in Cancer Care" for employers and benefits leaders aiming to improve cancer treatment and patient care. Learn about the benefits of clinical trials, strategies for boosting participation, and integrating trials into employer-sponsored health plans. #clinicalresearch #clinicaltrials #cancercare #employerbenefits #employerhealthplans
Today, PHM has released “The Importance of Clinical Trials in Cancer Care” whitepaper for benefit leaders. This report highlights the critical role of clinical trials in advancing cancer treatment, improving patient outcomes, and lowering costs for employers. Clinical trials are crucial for testing the safety and efficacy of new medical treatments and interventions. However, access to these trials has often been hindered by the clinical and scientific complexity of identifying and prioritizing appropriate trials. PHM is proud of its ability to bridge the gap between groundbreaking medical research and the patients who may benefit from it. Learn how integrating clinical trials into health plans can benefit both patients and employers: https://lnkd.in/gvgUavYm Read the press release: https://lnkd.in/gaSvV2_N Our thanks to PHM’s team of researchers and clinicians for their contribution to this whitepaper - Eva J. Gordon, PhD, Natalya Gertsik, PhD, Tommy Axford, Lee D. Gibbs, Ph.D., Ross Keller, PhD, Erika Sharpe, Amber McDonald, Julie Nowicki, and Zach Doran #clinicalresearch #clinicaltrials #cancercare #employerbenefits #employerhealthplans
The Importance of Clinical Trials in Cancer Care | PHM
solutions.privatehealth.com
-
?? From Setbacks to Solutions: Understanding the Hurdles in Alzheimer's Treatment Development - take away #1 from Braintale team AD/PD - Advances in Science & Therapy Despite the recent approval of lecanemab, the failure rate of clinical trials for drugs targeting CNS is higher than other systems. Developing drugs to cure Alzheimer remains a challenge for several reasons. ? 1?? The brain is a highly protected organ. The blood-brain barrier complicates the penetration of exogenous molecules in the brain while the cranium limits direct access to this organ.? 2?? Multiple pathways participate in the emergence and progression of Alzheimer’s disease. Alzheimer’s disease leads to heterogeneous traits from various phenotypes in complex interaction with the environment, resulting in broad potential therapeutic targets and difficult characterization of patients and their treatment susceptibility. 3?? Alzheimer’s disease starts way before the onset of symptoms. Clinical scores are only meaningful for patients at an advanced stage of the disease, when expected disease-modifying therapies would be less efficient. 4?? Challenging differential diagnosis. Alzheimer’s disease shares clinical and cognitive symptoms of dementia with other conditions including Lewy body or vascular dementias, or frontotemporal lobar degeneration. As a result, the identification, validation and use of new biomarkers is highly needed to better understand the disease itself and support the development of novel therapies ??? #Alzheimer #biomarkers #drugdevelopment #adpd2024 Julie Rachline, Vincent Perlbarg, Jean-Baptiste Martini, Helene Chausson, Florence Kocher, Camille de Solages, Arthur BEZIE, Adeline Verel, Bastien Lessenot, Iyèd Trimèche, Marine Bourgeais, Lisa Marcheval, Urielle Thoprakarn, Timmothy ?????? Dangeon, Martin Grange, Arthur Van der Veken, Natasha Soria, Hélène Bény, Thomas Moulin, Didier Cassereau, Laura Laughlin, Thierry Mignot, Joseph Barsey, PharmD. & LallianSe - Life Sciences Integrator
-
Summary: The FDA has expanded the orphan drug status for the immunotherapy SurVaxM, developed at Roswell Park, which shows promise in treating incurable brain cancer types. The expansion allows for potential use in various forms of pediatric and adult malignant gliomas. The vaccine is being developed to offer novel therapeutic options for patients with brain cancers beyond glioblastoma. Hashtags: #FDA #OrphanDrugDesignation #BrainCancer #Immunotherapy #RoswellPark Tip: Regular physical activity and a diet rich in fruits, vegetables, and whole grains can help reduce the risk of developing brain cancer and improve overall brain health. Additionally, incorporating stress-reducing activities like meditation or yoga into your routine can support brain health and overall well-being. Hashtags: #BrainHealth #CancerPrevention #HealthyLifestyle #DietandHealth #Mindfulness Read more here: https://lnkd.in/d96VMc9r BioMedHack.com is your leading source for the latest news, breakthroughs, and insights in medicine, biohacking, and alternative medicine. Our mission is to help you live healthier and longer by bringing you cutting-edge information and expert advice. Follow us on Facebook, Instagram, and X.
链接
mma.prnewswire.com
-
Our on-demand webinar features Dr. Matthew C. Havrda discussing neuroinflammation in Parkinson's disease is now available to stream. Learn how advanced assays are transforming research & clinical trials. #Neuroinflammation #Parkinsons
Driving Scientific Breakthroughs with Advanced Assay Development
go.quanterix.com
We're thrilled to say that we just joined the TBI Action Alliance this morning! Looking forward to working with everyone in the Alliance!